Erratum: MiR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin (Oncol Rep (2015) 33 (981‑989) DOI: 10.3892/or.2014.3657);MiR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 981-989

  Tian, Hang ^a   Hou, Lei ^b   Xiong, Yu Mei ^a   Huang, Jun Xiang ^a   She, Ying Jun ^a   Bi, Xiao Bao ^a   Song, Xing Rong ^a  

^a GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

^b SHANXI CANCER HOSPITAL   (China)

Author keywords

Chemosensitivity; Cisplatin; Esophageal squamous cell carcinoma; microRNAs; miR 218

Indexed keywords

CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 218; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; MIRN218 MICRORNA, HUMAN; MIRN218 MICRORNA, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ECA109 CELL LINE; ENZYME PHOSPHORYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA CELL LINE; TUMOR DEPTH; TUMOR INVASION; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL MOTION; CHEMISTRY; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84919432846     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2022.8265     Document Type: Erratum

References (44)

1. Enzinger PC and mayer RJ: Esophageal cancer. N Engl J med 349: 2241-2252, 2003.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. McCann J: Esophageal cancers: changing character, increasing incidence. Natl Cancer Inst 91: 497-498, 1999.
4. Demeester SR: Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 3 (Suppl 2): S2-S5, 2009.
5. Brennecke J and Cohen SM: Towards a complete description of the microRNA complement of animal Genomes. Genome biol 4: 228, 2003.
6. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
7. Bartel DP: microRNAs: genomics, bioGenesis, mechanism, and function. Cell 116: 281-297, 2004.
8. Carthew RW and Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell 136: 642-655, 2009.
9. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
10. Volinia S, Calin GA, Liu CG, et al: A microRNA expression sigNature of human solid tumors defnes cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
11. Croce CM: Causes and consequences of microRNA dysregu-lation in cancer. Nat Rev Genet 10: 704-714, 2009.
12. Rosenfeld N, Aharonov R, Meiri E, et al: microRNAs accurately identify cancer tissue origin. Nat biotechnol 26: 462-469, 2008.
13. Liang Y, Ridzon D, Wong L and Chen C: Characterization of microRNA expression profiles in normal human tissues. bmC Genomics 8: 166, 2007.
14. Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. mol Cancer 6: 60, 2007.
15. Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL and Yao GL: Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol 20: 6906-6911, 2014.
16. Gao C, Zhang Z, Liu W, Xiao S, Gu W and Lu H: Reduced microRNA-218 expression is associated with high nuclear factor kappa b activation in gastric cancer. Cancer 116: 41-49, 2010.
17. Yu J, Wang Y, Dong R, Huang X, Ding S and Qiu H: Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol 138: 671-674, 2012.
18. Venkataraman S, Birks DK, Balakrishnan I, et al: microRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated Genes in medulloblastoma. J Biol Chem 288: 1918-1928, 2013.
19. Zhang C, Ge S, Hu C, Yang N and Zhang J: miRNA-218, a new regulator of HmGb1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim biophys Sin (Shanghai) 45: 1055-1061, 2013.
20. Liu Y, Yan W, Zhang W, et al: miR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Rep 28: 1013-1021, 2012.
21. Prudnikova TY, Mostovich LA, Kashuba VI, Ernberg I, Zabarovsky ER and Grigorieva EV: miRNA-218 contributes to the regulation of D-glucuronyl C5-epimerase expression in normal and tumor breast tissues. Epigenetics 7: 1109-1114, 2012.
22. Yang L, Li Q, Wang Q, Jiang Z and Zhang L: Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway. biomed Pharmacother 66: 535-540, 2012.
23. Li J, Ping Z and Ning H: miR-218 impairs tumor Growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J mol Sci 13: 16053-16064, 2012.
24. Yang M, Liu R, Sheng J, et al: Differential expression profles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep 29: 169-176, 2013.
25. Andl CD, Mizushima T, Nakagawa H, et al: Epidermal Growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem 278: 1824-1830, 2003.
26. Sakai NS, Samia-Aly E, Barbera M and Fitzgerald RC: A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer biol 23: 512-521, 2013.
27. Luthra R, Singh RR, Luthra MG, et al: microRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 27: 6667-6678, 2008.
28. Kan T, Sato F, Ito T, et al: The miR-106b-25 polycistron, activated by genomic amplifcation, functions as an Oncogene by suppressing p21 and bim. Gastroenterology 136: 1689-1700, 2009.
29. Lee KH, Goan YG, Hsiao M, et al: microRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 315: 2529-2538, 2009.
30. Fassan M, Volinia S, Palatini J, et al: microRNA expression profling in human Barrett's carcinoGenesis. Int J Cancer 129: 1661-1670, 2011.
31. Zhang M, Zhou S, Zhang L, et al: miR-518b is downregulated, and involved in cell proliferation and invasion by targeting Rap1b in esophageal squamous cell carcinoma. FEbS Lett 586: 3508-3521, 2012.
32. Wang Z, Qiao Q, Chen M, et al: miR-625 downregulation promotes proliferation and invasion in esophageal cancer by targeting Sox2. FEbS Lett 588: 915-921, 2014.
33. Wang Y, Zang W, Du Y, et al: mir-655 upregulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma. J Transl med 11: 301, 2013.
34. Calin GA and Croce CM: microRNA sigNatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
35. Manikandan J, Aarthi JJ, Kumar SD and Pushparaj PN: Oncomirs: the potential role of non-coding microRNAs in understanding cancer. bioinformation 2: 330-334, 2008.
36. Song L, Huang Q, Chen K, et al: miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-β. Biochem biophys Res Commun 402: 135-140, 2010.
37. Shi J, Yang L, Wang T, et al: miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. molmed Rep 8: 1111-1117, 2013.
38. Hassan MQ, Maeda Y, Taipaleenmaki H, et al: miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem 287: 42084-42092, 2012.
39. Tie J, Pan Y, Zhao L, et al: miR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6: e1000879, 2010.
40. Yamamoto N, Kinoshita T, Nohata N, et al: Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol 42: 1523-1532, 2013.
41. Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083, 2010.
42. Huang Y, Xi Q, Chen Y, et al: A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Anticancer Drugs 24: 889-898, 2013.
43. Uesugi A, Kozaki K, Tsuruta T, et al: The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 71: 5765-5778, 2011.
44. Xiao ZD, Jiao CY, Huang HT, et al: miR-218 modulate hepatocellular carcinoma cell proliferation through PTEN/AKT/PI3K pathway and HoxA10. Int J Clin Exp Pathol 7: 4039-4044, 2014.